immatics biotechnologies GmbH

Immatics N.V. a clinical-stage biopharmaceutical company focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors which is in Phase 1b clinical trial; IMA203CD8 a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma which is in preclinical stage; and IMA30x an allogenic cellular therapy product candidate which is in preclinical stage. The company also develops TCR Bispecifics products including IMA401 which is in Phase 1b clinical trial; and IMA402 and IMA403 which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen Germany.